IN THE NEWS: Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma

The ASCO Post

Jeffrey Zonder, M.D., leader of the Multiple Myeloma and Amyloidosis Program and member of the Hematology Oncology Multidisciplinary Team, reports on updates on the REGN5458 study, looking into targeting BCMA and CD3.

Read the full article here.